Global Neurological Biomarkers Market is Expected to Reach $18.9 Billion by 2031: Says AMR
September 27, 2022 12:00 ET
|
Allied Market Research
Portland, OR, Sept. 27, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Neurological Biomarkers Market size was estimated at $5.4 billion...
U.S. Patent Office Issues Trethera Composition of Matter Patent Covering TRE-515, Extending Market Exclusivity to Late 2041
September 20, 2022 12:47 ET
|
Trethera Corporation
LOS ANGELES, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models
September 07, 2022 12:37 ET
|
Trethera Corporation
LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis
August 30, 2022 10:37 ET
|
Trethera Corporation
LOS ANGELES, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of...
Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041
August 17, 2022 12:38 ET
|
Trethera Corporation
LOS ANGELES, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
August 15, 2022 07:00 ET
|
Clene Inc.
CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT...
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis
August 09, 2022 12:47 ET
|
Trethera Corporation
LOS ANGELES, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
NeurologyLive® Announces Giants of Multiple Sclerosis™ Inaugural Class of Inductees
June 03, 2022 09:56 ET
|
NeurologyLive®
CRANBURY, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- NeurologyLive® and the Consortium of Multiple Sclerosis Centers (CMSC) today announced the inaugural class of Giants of Multiple Sclerosis™...
Multiple Sclerosis Drugs Market Size & Trends 2022 - 2028 [CAGR 3.9%] | Industry Share, Growth by Fortune Business Insights
May 30, 2022 04:00 ET
|
Fortune Business Insights
Pune, India, May 30, 2022 (GLOBE NEWSWIRE) -- The global multiple sclerosis drugs market size was worth USD 23.68 billion in 2021. The market valuation is projected to increase from USD 25.43...
Neurodegenerative Diseases Market to reach USD 53 Billion by 2030 and grow steadily at a CAGR of 3.2%: Straits Research
May 27, 2022 11:30 ET
|
Straits Research
New York, United States, May 27, 2022 (GLOBE NEWSWIRE) -- Neurodegenerative diseases are a large and diverse group of disorders characterized by progressive deterioration of the function and...